S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
S&P 500   2,526.90 (+2.28%)
DOW   21,413.44 (+2.24%)
QQQ   186.01 (+2.03%)
AAPL   244.93 (+1.67%)
FB   158.19 (-0.88%)
MSFT   155.26 (+2.07%)
GOOGL   1,117.03 (+1.35%)
AMZN   1,918.83 (+0.58%)
CGC   13.80 (+1.62%)
NVDA   255.47 (+5.10%)
BABA   188.90 (+0.71%)
MU   41.09 (+3.01%)
GE   6.90 (-1.99%)
TSLA   454.47 (-5.63%)
AMD   44.49 (+1.90%)
T   28.76 (+2.53%)
ACB   0.83 (+2.46%)
F   4.36 (-0.91%)
NFLX   370.08 (+1.65%)
BAC   20.57 (+4.05%)
GILD   76.98 (+6.16%)
PRI   82.76 (-1.66%)
DIS   96.97 (+2.16%)
Log in

NASDAQ:QURE - Uniqure Stock Price, Forecast & News

$46.96
+1.33 (+2.91 %)
(As of 04/2/2020 04:00 PM ET)
Today's Range
$44.78
Now: $46.96
$47.55
50-Day Range
$40.01
MA: $51.59
$64.88
52-Week Range
$36.20
Now: $46.96
$82.49
Volume105,800 shs
Average Volume454,438 shs
Market Capitalization$2.08 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.1
uniQure N.V., a gene therapy company, engages in the discovery, development, and commercialization of gene therapies in the Netherlands. It engages in developing AMT-061, a gene therapy that is in Phase III clinical trial for the treatment of hemophilia B; AMT-060, which is in Phase I/II clinical trial to treat hemophilia B; AMT-130, a gene therapy for the treatment of Huntington's disease; and AMT-126, for the treatment of heart failure. In addition, the company engages in developing AMT-180, an one-time intravenously-administered gene therapy candidate, which is in preclinical stage for the treatment hemophilia A; AMT-190, a differentiated gene therapy for the treatment of Fabry disease; and AMT-150, a gene therapy for SCA3, a central nervous system disorder. The company has collaboration and license agreements with Bristol Myers-Squibb; 4D Molecular Therapeutics, LLC; and Synpromics. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More
Uniqure logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:QURE
CUSIPN/A
Phone31-20-240-6000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7.28 million
Book Value$7.41 per share

Profitability

Net Income$-124,200,000.00
Net Margins-1,705.82%

Miscellaneous

Employees212
Market Cap$2.08 billion
Next Earnings Date5/4/2020 (Estimated)
OptionableOptionable

Receive QURE News and Ratings via Email

Sign-up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.


Uniqure (NASDAQ:QURE) Frequently Asked Questions

How has Uniqure's stock been impacted by COVID-19 (Coronavirus)?

Uniqure's stock was trading at $47.54 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, QURE stock has decreased by 1.2% and is now trading at $46.96. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Uniqure?

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Uniqure in the last year. There are currently 1 hold rating and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Uniqure.

When is Uniqure's next earnings date?

Uniqure is scheduled to release its next quarterly earnings announcement on Monday, May 4th 2020. View our earnings forecast for Uniqure.

How were Uniqure's earnings last quarter?

Uniqure NV (NASDAQ:QURE) posted its quarterly earnings data on Monday, March, 2nd. The biotechnology company reported ($0.97) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.78) by $0.19. The biotechnology company earned $2.63 million during the quarter, compared to analyst estimates of $1.76 million. Uniqure had a negative return on equity of 51.62% and a negative net margin of 1,705.82%. View Uniqure's earnings history.

What price target have analysts set for QURE?

13 Wall Street analysts have issued 12 month target prices for Uniqure's stock. Their forecasts range from $73.00 to $105.00. On average, they anticipate Uniqure's stock price to reach $86.00 in the next twelve months. This suggests a possible upside of 83.1% from the stock's current price. View analysts' price targets for Uniqure.

What are Wall Street analysts saying about Uniqure stock?

Here are some recent quotes from research analysts about Uniqure stock:
  • 1. According to Zacks Investment Research, "UNIQURE B.V. is involved in developing gene therapy for patients of genetic or acquired diseases. It offers Glybera for the treatment of lipoprotein lipase deficiency, an orphan metabolic disease. The company's product pipeline includes which are in clinical trials are additional adeno-associated virus consist of AMT-060, AMT-021, AMT-110 and AAV2/glial. UNIQURE B.V. is headquartered in Amsterdam, the Netherlands. " (1/23/2020)
  • 2. HC Wainwright analysts commented, "Enrollment completion in the HOPE-B registration study positions 12+month lead. We now anticipate data during 4Q20, with likely commercial launch during 4Q21, ahead of our prior 2H-2022 expectations. We continue to believe, AMT-061 remains the one-and-done therapy of choice based on: (1) the ability to successfully treat subjects with NAB’s to the peer construct; (2) low-levels of NABs to AAV5, which is a significant commercial differentiator, compelling centers to choose a therapy that could benefit the majority of patients i.e., >90% in case of AMT-061, over one with at least 40% exclusion criteria; and (3) no prophylactic steroids." (9/3/2019)
  • 3. Chardan Capital analysts commented, "We continue our bullish QURE thesis (and affirm our $175 price target) ahead of what we see as among the most compelling 2020 catalysts in biotech:." (9/3/2019)

Has Uniqure been receiving favorable news coverage?

News coverage about QURE stock has been trending very negative recently, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Uniqure earned a media sentiment score of -3.3 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View the latest news aboutUniqure.

Are investors shorting Uniqure?

Uniqure saw a decline in short interest during the month of March. As of March 13th, there was short interest totaling 4,136,000 shares, a decline of 9.5% from the February 27th total of 4,570,000 shares. Based on an average trading volume of 427,500 shares, the short-interest ratio is presently 9.7 days. Approximately 19.7% of the shares of the company are sold short. View Uniqure's Current Options Chain.

Who are some of Uniqure's key competitors?

What other stocks do shareholders of Uniqure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Uniqure investors own include Empire Resorts (NYNY), Micron Technology (MU), Alibaba Group (BABA), Exelixis (EXEL), NVIDIA (NVDA), Gilead Sciences (GILD), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH), Roku (ROKU) and AbbVie (ABBV).

Who are Uniqure's key executives?

Uniqure's management team includes the following people:
  • Mr. Matthew Craig Kapusta, CEO, Interim CFO & Exec. Director (Age 47)
  • Dr. Sander van Deventer M.D., Ph.D., Co-founder, Chief Scientific Officer & GM of Amsterdam (Age 65)
  • Mr. Jonathan Garen, Chief Bus. Officer (Age 53)
  • Prof. Hugo Katus, Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany
  • Dr. Scott T. McMillan, Chief Operations Officer (Age 60)

What is Uniqure's stock symbol?

Uniqure trades on the NASDAQ under the ticker symbol "QURE."

How do I buy shares of Uniqure?

Shares of QURE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Uniqure's stock price today?

One share of QURE stock can currently be purchased for approximately $46.96.

How big of a company is Uniqure?

Uniqure has a market capitalization of $2.08 billion and generates $7.28 million in revenue each year. The biotechnology company earns $-124,200,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis. Uniqure employs 212 workers across the globe. View additional information about Uniqure.

What is Uniqure's official website?

The official website for Uniqure is http://www.uniqure.com/.

How can I contact Uniqure?

Uniqure's mailing address is PAASHEUVELWEG 25A, AMSTERDAM P7, 1105 BP. The biotechnology company can be reached via phone at 31-20-240-6000 or via email at [email protected]


MarketBeat Community Rating for Uniqure (NASDAQ QURE)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  570 (Vote Outperform)
Underperform Votes:  412 (Vote Underperform)
Total Votes:  982
MarketBeat's community ratings are surveys of what our community members think about Uniqure and other stocks. Vote "Outperform" if you believe QURE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe QURE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel